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1040Brain Imaging Changes Associated
With Risk Factors for Cardiovascular and
Cerebrovascular Disease in Asymptomatic PatientsABSTRACTReviews of imaging studies assessing the brain effects of vascular risk factors typically include a substantial number of
studies with subjects with a history of symptomatic cardiovascular or cerebrovascular disease and/or events, limiting our
ability to disentangle the primary brain effects of vascular risk factors from those of resulting brain and cardiac damage.
The objective of this study was to perform a systematic review of brain changes from imaging studies in patients with
vascular risk factors but without clinically manifest cardiovascular or cerebrovascular disease or events. The 77 studies
included in this review demonstrate that in persons without symptomatic cardiovascular, cerebrovascular, or peripheral
vascular disease, the vascular risk factors of hypertension, diabetes mellitus, obesity, hyperlipidemia, and smoking are all
independently associated with brain imaging changes before the clinical manifestation of cardiovascular or cerebrovas-
cular disease. We conclude that the identiﬁcation of brain changes associated with vascular risk factors, before the
manifestation of clinically signiﬁcant cerebrovascular damage, presents a window of opportunity wherein adequate
treatment of these modiﬁable vascular risk factors may prevent the development of irreversible deleterious brain
changes and potentially alter patients’ clinical course. (J Am Coll Cardiol Img 2014;7:1039–53) © 2014 by the American
College of Cardiology Foundation.R isk factors for cardiovascular and cerebro-vascular disease, whether they result inclinically signiﬁcant vascular events or not,
have been associated with pathological brain
changes related to cognitive dysfunction such as
vascular dementia (VaD) and Alzheimer’s disease
(1–3). These same vascular risk factors (VRFs) have
also been associated with more subtle forms of
cognitive impairment than those associated with
these brain pathologies (4). For example, the
concept of vascular cognitive impairment has been
invoked to describe those patients with cognitive
impairment and risk of VaD but not meeting criteria
for VaD (5).SEE PAGE 1054There have been several published reviews cata-
loguing brain imaging changes in association with
risk factors for cardiovascular and cerebrovascular
disease. However, these reviews typically include a
substantial number of studies with subjects with a
history of symptomatic cardiovascular and/or cere-
brovascular disease and/or events. Indeed, decline in
cognitive abilities has been related directly to strokes
(6) and severe cardiovascular disease in the absence
of clinically identiﬁed stroke (7,8), particularly in cases
of heart failure (9). By extrapolation, these same sub-
jects harbor signiﬁcant brain dysfunction directly
related to strokes and cardiovascular disease.Therefore, a major limitation of reviews of brain
changes associated with VRFs published to date is the
inability to disentangle the primary brain effects of
VRFs from the brain effects of symptomatic cardio-
vascular and cerebrovascular end-organ damage. To
characterize the nature of brain imaging changes
associated primarily with VRFs, we conducted a sys-
tematic review of brain imaging studies carried out in
patients with risk factors for cardiovascular and cere-
brovascular disease but without a diagnosis of cardio-
vascular, cerebrovascular, or peripheral vascular
disease or events.
METHODS
This systematic review was conducted following the
guidelines of the PRISMA statement (10).
STUDY SELECTION. Studies included in this review
report the results of brain imaging investigations of
persons with any of the following risk factors for
cardiovascular or cerebrovascular disease: hyperten-
sion (HTN), diabetes mellitus (DM), increased
adiposity, hyperlipidemia, smoking, and metabolic
syndrome (MetS). Included studies assessed the as-
sociation between these VRFs and ﬁndings with all
brain structural and functional imaging modalities
available. This review is limited to English-language
publications from 1980 to August 31, 2013. Published
studies were excluded if: 1) subjects were younger
AB BR E V I A T I O N S
AND ACRONYM S
BMI = body mass index
BP = blood pressure
DBP = diastolic blood pressure
DM = diabetes mellitus
fMRI = functional magnetic
resonance imaging
GM = gray matter
HbA1c = glycosylated
hemoglobin
HDL = high-density lipoprotein
HTN = hypertension
LDL = low-density lipoprotein
MRI = magnetic resonance
imaging
MetS = metabolic syndrome
SBI = silent brain infarct
SBP = systolic blood pressure
VaD = vascular dementia
VRF = vascular risk factor
WM = white matter
WMH = white matter
hyperintensity
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1041than 18 years of age; 2) subjects carried a diagnosis
of dementia (i.e., Alzheimer’s disease, VaD) or other
primary neurological condition associated with
brain dysfunction; 3) subjects had a diagnosis of a
psychiatric disorder except depression; 4) subjects
had a history of cerebrovascular accident, transient
ischemic attack, symptomatic infarcts on magnetic
resonance imaging (MRI), or the methodology made
no mention of the exclusion of such subjects; 5) $5%
of the study cohort had a diagnosis of coronary artery
disease, myocardial infarction, congestive heart fail-
ure, and peripheral vascular disease and if a <5%
prevalence rate was present in the sample, no sub-
analyses were carried out excluding subjects with
those diagnoses or no statistical adjustment was
performed to control for the effects of these di-
agnoses; and 6) no statistical correction for the effects
of age, sex, and the effects of other VRFs not the
primary focus of investigation.
SEARCH STRATEGY. Studies were identiﬁed by
searching the following electronic databases: MED-
LINE, CINAHL, and Cochrane Database of Systematic
Review using the following search terms: “vascular
risk factor,” “hypertension,” “diabetes,” “obesity,”
“hyperlipidemia,” “smoking,” “metabolic syndrome,”
“brain,” “imaging,” “magnetic resonance imaging
(MRI),” “fMRI,” “DTI”, “PET,” and “computed to-
mography (CT).” References of review papers were
searched to identify studies that might have been
overlooked in the initial search. Six of the authors
(J.F., C.T., G.G., H.D., L.C., and P.D.) reviewed ab-
stracts of all citations from the search and the full
papers for inclusion. The ﬁnal decision to include
studies was on the basis of the inclusion and
exclusion criteria and a review of the full text pa-
pers by the primary author (J.I.F.).
DATA EXTRACTION. We developed a data extraction
sheet and had 6 review authors (J.F., C.T., G.G., H.D.,
L.C., P.D.) extract the following data from included
studies with the primary author (J.I.F.), checking the
extracted data for its integrity and accuracy: 1) num-
ber of study subjects in each group; 2) demographic
characteristics of subjects (i.e., age, sex, ethnicity);
3) VRF being assessed; 4) presence of symptomatic
cardiovascular, cerebrovascular, or peripheral vas-
cular disease; 5) whether prevalence of vascular
disease $5%, was a subanalysis performed excluding
those subjects with disease or were statistical ana-
lyses performed to control for the effects of vascular
disease; 6) the presence of other VRFs and, if present,
was a subanalysis performed excluding those subjects
with multiple risk factors or were statistical analyses
performed to control for the effects of the other VRFs;8) onset (i.e., mid-life, late life) and length of
exposure to risk factor; 9) treatment of VRFs,
analyses of effects of treatment; 9) imaging
modality; 10) all structural and functional
imaging outcomes; and 11) correlations be-
tween imaging variables and neuropsycho-
logical test performance.
RESULTS
To better understand the data presented in
this review, a summary of neuroimaging
acronyms referenced herein is provided in
Table 1. A total of 77 published studies of the
effects of HTN, DM, increased adiposity,
hyperlipidemia, smoking, and MetS on brain
structural and functional imaging ﬁndings
are included in this review. A concise sum-
mary of the more salient ﬁndings of the ef-
fects of these VRFs and their treatment on
brain structure and function is presented in
Table 2.
I. HYPERTENSION. A total of 22 published
brain imaging studies of HTN effects are
included in this review (Online Table 1).Structural brain changes. Global changes. Whole-brain
volume reduction has been associated with a diag-
nosis of HTN (11). Other global changes associated
with HTN include brain cerebrospinal ﬂuid space
enlargement (12,13).
Gray matter changes. HTN has been associated with
brain gray matter (GM) volume reductions in cross-
sectional studies, with a heterogeneous pattern of
these volume reductions between studies (12–14). It
is possible that the confounding effects of aging
may partially contribute to the discrepancies in
location of HTN-related GM reductions between
studies. In support of this supposition is the ﬁnding
of Strassburger et al. (13), who, when considering the
interaction of aging and a diagnosis of HTN, extended
their ﬁndings from the thalamus to include atrophy
of the frontal cortices of the brain. However, when
a more continuous variable such as blood pressure
(BP) was used, a more complex U-shaped association
of brain cortical atrophy with concurrent diastolic
blood pressure (DBP) emerges (15). DBP outside an
ideal range of 65 to 74 mm Hg has been associated
with brain cortical atrophy, including both elevated
(>85 mm Hg) and reduced (<65 mm Hg) DBP (15).
Longitudinal relationships between BP and brain
GM volume have been more inconsistent. These in-
consistencies include some reports of HTN-associated
brain GM volume loss over time (16), whereas some
TABLE 1 Summary of Referenced Neuroimaging Acronyms
Imaging Acronym Acronym Expansion Imaging Modality Explanation of Imaging Outcome
[O15]H2O PET Positron emission tomography
using oxygen 15–labeled water
PET A form of PET using a freely diffusible tissue tracer [O15]H2O
to calculate regional cerebral blood ﬂow
AD Axial diffusivity MRI (DTI) The measure of restriction along the axis of the axons
(perpendicular to the direction of radial diffusivity). AD is a
more speciﬁc index of axonal degeneration.
BOLD Blood oxygen level dependent MRI The principal mechanism of signal contrast in fMRI produced
by a combination of brain neuronal oxygen consumption
(oxygenation state of hemoglobin is measured) and blood
ﬂow. The BOLD signal is associated with brain neuronal
activation, more activation ¼ increased BOLD.
Cho Choline MRS A metabolite quantiﬁed in the brain by MRS. Cho is a marker
of cellular membrane turnover reﬂecting cellular
proliferation. Increased Cho can be seen in malignancy,
infarction, and inﬂammation.
Cr Creatine MRS A metabolite quantiﬁed in the brain by MRS. Cr is considered a
marker of intracellular metabolism. It is considered a stable
brain metabolite.
DA D2 receptor
binding potential
Dopamine D2 receptor
subtype occupancy
PET ([11C]raclopride PET) [11C]Raclopride ligand PET scanning is used to determine
changes in brain DA D2 receptor binding potential, which
indexes changes in DA release in the brain.
DMN Default mode network MRI (fMRI) A brain functional network, the activity of which is measured
during resting state fMRI. This network of brain regions is
normally engaged when patients are left to think to
themselves undisturbed; composed of medial temporal lobe,
prefrontal cortex, posterior cingulate, and parietal cortex.
DTI Diffusion tensor imaging MRI DTI produces MRI indexes of white matter integrity and axonal
bundle formation and geometries.
FA Fractional anisotropy MRI (DTI) An index of myelination or white matter integrity and/or
organization. FA is expressed as a number on a scale
between 0 and 1, without any unit of measure. The greater
the FA, the greater the integrity/organization of the white
matter tract.
FC Functional connectivity MRI or PET Time synchronous activation between multiple distant
brain regions.
FDG-PET Fluorodeoxyglucose positron
emission tomography
PET Scanning technique measuring glucose metabolism in the brain
using a radiolabeled glucose analogue.
fMRI Functional magnetic
resonance imaging
MRI Stimulus-driven brain activation measured from the changes in
oxygenation states of hemoglobin.
GM volume Gray matter volume MRI The volume of the brain GM can be expressed as a global or
region-speciﬁc measure. GM in the brain contains the cell
bodies, dendrites, and axon terminals of neurons.
MAO-A Monoamine oxidase A PET ([11C]clorgyline PET) MAO-A metabolizes serotonin, norepinephrine, and dopamine.
PET using [11C]clorgyline measures brain MAO-A.
MAO-B Monoamine oxidase B PET (deuterium substituted
[11C]-L-deprenyl PET)
MAO-B primarily metabolizes dopamine. PET using deuterium
substituted [11C]-L-deprenyl measures brain MAO-B.
MD Mean diffusivity MRI (DTI) Also referred to as the apparent diffusion coefﬁcient (ADC).
It is a measure of diffusion (Brownian motion) of water
molecules in tissue measured in mm2/s. MD is affected by
restricted spaces, barriers such as cell membranes, tubules,
and macromolecules. ADC maps of the brain can be
generated, and good diffusion is bright on these maps.
MRS Magnetic resonance spectroscopy MRS An imaging technique based on MRI that allows one to
visualize certain metabolite concentrations in brain tissue;
either single-voxel spectra or metabolite images can be
produced (MRS imaging). The major peaks of the 1H-MRS
spectrum (each peak represent a metabolite) reported in
this review include N-acetylaspartate (NAA), creatine (Cr),
and choline (Cho) containing phospholipids.
NAA N-Acetylaspartate MRS A metabolite quantiﬁed in the brain by MRS. NAA is considered
a metabolic marker reﬂecting the functional status of
neurons and axons in the brain, with a decrease indicating
neuronal or axonal loss or dysfunction.
NAA/Cr, NAA/Cho N-Acetylaspartate ratios
with Cr/Cho
MRS The concentration of Cr is relatively constant and is considered a
stable brain metabolite; therefore, it is used as an internal
reference for calculating metabolite ratios such as NAA. Cho is
also used as an internal reference for calculating NAA ratios.
[O15]H2O PET Positron emission tomography using
oxygen 15–labeled water
PET A form of PET using a freely diffusible tissue tracer, [O15]H2O,
to calculate regional cerebral blood ﬂow.
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TABLE 1 Continued
Imaging Acronym Acronym Expansion Imaging Modality Explanation of Imaging Outcome
rCBF Regional cerebral blood ﬂow 99Tc-HMPAO SPECT
133Xe SPECT
[O15] water PETdynamic
susceptibility contrast
MRI
The volume of blood traversing a brain region per unit of time
(ml/100 g/min). rCBF is measured using SPECT (single-
photon emission tomography) with 99Tc-HMPAO, 133Xe
SPECT, [O15]H2O PET, or dynamic susceptibility contrast
MRI.
rCBV Regional cerebral blood volume MRI Total volume of blood traversing a brain region measured in
ml/100 g of brain tissue, commonly obtained using
contrast-enhanced MRI.
rCMRglu Regional cerebral glucose
metabolic rate
PET (ﬂuorodeoxyglucose-
PET)
Metabolic rate of glucose in the brain.
RD Radial diffusivity MRI (DTI) Measures the degree of restriction due to the presence of the
myelin sheath (i.e., perpendicular to the axonal ﬁbers).
Radial diffusivity is modulated by myelin in white matter
and therefore is a more speciﬁc index of myelin pathology.
rsFDG-PET Resting state ﬂuorodeoxyglucose
positron emission tomography
PET Glucose metabolic activity measured during resting state.
rsfMRI Resting state functional MRI MRI Functional connectivity measured using MRI with a subject at
wakeful rest and not performing any goal-oriented task.
VT/fP Total volume of the radioligand 2FA
corrected for fraction in free plasma
PET (2FA-PET) The 2FA radioligand PET imaging procedure is used to quantify
the a-4b-2 nicotinic acetylcholine receptor in the brain.
WM volume White matter volume MRI Volume of the brain white matter can be expressed as a global
or region-speciﬁc measure. White matter is composed of
axons connecting different regions of gray matter in the
brain to each other.
WMH
Note: The commonly accepted
categorization of WMH is as
follows:
1. PVWMH
2. DWMH
White matter hyperintensity
1. Periventricular white
matter hyperintensity
2. Deep white matter hyperintensity
MRI These are hyperintense areas seen on T2-ﬂuid attenuated
inversion recovery magnetic resonance images. WMHs are
seen in normal aging and are also correlated with enlarged
perivascular spaces, demyelination, or gliosis; localized
pathological changes in the white matter of the brain due
to chronic hypoperfusion by arteriolosclerotic changes to
the brain microvasculature.
1. WMH lining the lateral ventricles.
2. WMH located in the remaining WM, not adjacent to the
lateral ventricles.
99Tc-HMPAO ¼ technetium 99 hexamethyl-propyl creatinine oxime.
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1043report no volume loss (17,18). In addition, some
studies report higher DBP associated with greater
brain GM volume loss over time (15), whereas others
report higher SBP associated with greater volume loss
(19).
When considering the effects of pharmacological
treatment of HTN on brain GM volumetric changes, 2
outcomes emerge: 1) pharmacological treatment of
HTN fails to prevent increased brain GM loss over
time (14,16,19); and 2) pharmacological treatment of
HTN results in either a reduction or acceleration
of brain GM volume loss over time, the direction
dependent on the timing of treatment initiation and
the magnitude of BP reduction. For example, in-
vestigators have shown that higher DBP in midlife
predicts more brain GM volume loss late in life when
antihypertensive medication is not used, whereas
this relationship is lost when antihypertensive
medication is used (15). However, when antihyper-
tensive use is initiated late in life instead of midlife, it
is associated with more pronounced brain GM loss,particularly when there is a steeper decrease in DBP
(15).
White matter changes. Cross-sectional investigations
have shown a diagnosis of HTN to be associated with
loss of prefrontal brain white matter (WM) volume
(14) and a variable pattern of MRI-identiﬁed WM
hyperintensity (WMH) increases with respect to
overall burden and location in the brain (11,13,14,19).
WMHs are localized pathological changes in the WM
of the brain caused by chronic hypoperfusion of the
WM by arteriolosclerotic changes to the brain micro-
vasculature, and thus WMHs can be considered an
MRI index of brain microvascular pathology. Indeed,
the relationship between HTN and the MRI index
of brain microvascular disease assumes a J-shaped
function when nocturnal BP changes are considered,
wherein hypertensive patients with extreme noc-
turnal BP dips (>20% decrease from awake systolic
blood pressure [SBP]) and those with no signiﬁcant
nocturnal dips (<10% decrease from awake SBP) show
an increased MRI index of brain microvascular
TABLE 2 Summary of the Effects of VRFs and Their Treatment on Structural and Functional Brain Imaging
VRF Structural Imaging Findings
Treatment Effects on VRF-Related
Structural Imaging Findings Functional Imaging Findings
Treatment Effects on VRF-Related
Functional Imaging Findings
HTN 1. HTN is associated with whole-
brain volumetric reductions.
2. HTN is associated with a variable
pattern of gray matter volu-
metric reductions across studies.
3. HTN is associated with a variable
pattern of increased WMH
burden across studies.
4. Hypertensive patients with
extreme or no nocturnal dips in
SBP have greater WMH burden
compared with hypertensive pa-
tients with moderate nocturnal
dips in BP.
1. Higher DBP is associated
with more cortical atrophy
over 20 years in untreated
hypertensive patients, but
not in treated
hypertensive patients.
2. Reduction in BP to normo-
tensive levels in hyperten-
sive patients with treatment
fails to prevent gray matter
loss over 1 year.
3. Antihypertensive use in
hypertensive patients in late
life, but not midlife is asso-
ciated with more cortical
atrophy.
1. HTN is associated with reduced
resting state gCBF and rCBF.
2. A greater duration of HTN is
associated with a greater reduction
in resting state CBF.
3. HTN is associated with an altered
pattern of cognitive activation
rCBF responses.
4. HTN is associated with reduced
correlations of rCMRglu between
synchronized brain regions (i.e.,
reduction of functional network
connectivity).
1. Antihypertensive treatment
reverses/mutes HTN-related
decreases in resting state and
cognitive task activated gCBF
and rCBF.
2. The quality of BP control in
hypertensive patients is positively
correlated with resting state gCBF
and rCBF.
3. Antihypertensive treatment
increases correlations in cognitive
task–related rCBF between regions
associated with task performance
(limited evidence).
4. After 36 months of antihypertensive
treatment, there is a return to
pre-treatment reduced levels of
CBF in hypertensive patients
(limited evidence).
DM 1. No consensus on the association
of DM with global GM volumetric
reductions.
2. No consensus on the association
of DM with WMH burden.
3. Type 1 DM is associated with a
variable pattern of WM FA re-
ductions across studies.
1. The quality of glycemic
control (HbA1c) is associated
with the magnitude of WMH
burden (limited evidence).
2. The quality of glycemic
control (HbA1c) is associated
with FA in the corona radiata
and optic radiations (limited
evidence).
1. DM is associated with lower
resting state rCBF (limited
evidence).
2. DM is associated with a
redistributed pattern of cognitive
task–related rCMRglu (limited
evidence).
3. Types 1 and 2 DM are associated with
reduced functional connectivity in
default mode network and other
various cognitive networks on fMRI.
No treatment data available.
Adiposity 1. Increased adiposity is associated
with decreased total
cerebral volume.
2. Increased BMI is associated with
a variable pattern of GM volu-
metric reductions across studies.
3. No consensus on the association
of BMI with WM volumetric
changes.
4. No association between indexes
of adiposity and burden of WMHs
(limited data).
1. Greater aerobic ﬁtness is
associated with greater FA in
the cingulum (limited data).
1. Increased BMI is associated with
decreased resting state rCBF
(limited data).
2. Increased BMI is associated with
reduced rCMRglu in bilateral pre-
frontal and anterior cingulate re-
gions (limited data).
No treatment data available.
Hyperlipidemia 1. Higher total cholesterol and
LDL are associated with lower
GM volume (limited evidence).
2. Higher total cholesterol and
LDL are associated with lower FA
in WM of the right hemisphere
(limited evidence).
3. No association between familial
hypercholesterolemia and
burden of WMHs.
1. No effects of lipid-lowering
medications on the LDL- or
cholesterol-related FA
decreases observed in the
right hemisphere (limited
evidence).
1. Hypertriglyceridemia is
associated with temporal lobe
hypoperfusion.
2. Higher serum total cholesterol is
associated with lower rCMRglu
in the precuneus, prefrontal, pari-
etotemporal, and frontal
regions (limited evidence).
3. Higher cholesterol-related genetic
scores (CREGG) are associated
with lower rCMRglu in the posterior
cingulate, precuneus, parietotemporal,
and frontal regions (limited evidence).
The association between higher total
cholesterol with lower rCMRglu in
the precuneus, prefrontal,
parietotemporal, and frontal
regions remain signiﬁcant after
controlling for statin use
(limited data).
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1044pathology, whereas those with less extreme
nocturnal BP dips (10% to 20% decrease from awake
SBP) show no increases in the MRI index of brain
microvascular pathology (20). Over time, the burden
of the MRI index of brain microvascular pathology
increases in hypertensive patients (19), with some
reports showing SBP increases to be more important
in this process (17,21), and others DBP increases
(22,23). Finally, the impaired cognitive function of
hypertensive patients has been attributed to thisincreased MRI index of brain microvascular pathology
(22). The pharmacological treatment of HTN has been
reported to increase the MRI index of brain micro-
vascular pathology compared with untreated hyper-
tensive patients (24). The same study also reported
greater disorganization of the brain white matter ﬁber
tracts that connect brain regions (indexed on MRI as
lower fractional anisotropy values) in treated
compared with untreated hypertensive patients (24).
However, these results are confounded by the
TABLE 2 Continued
VRF Structural Imaging Findings
Treatment Effects on VRF-Related
Structural Imaging Findings Functional Imaging Findings
Treatment Effects on VRF-Related
Functional Imaging Findings
Smoking 1. Smoking is associated with
smaller total brain volume
(limited evidence).
2. Greater lifetime exposure to
tobacco associated with smaller
total brain volume (limited
evidence).
3. Smoking is associated with
a variable pattern of GM volu-
metric reductions across studies.
4. Greater lifetime exposure to to-
bacco is associated with greater
GM volume reductions.
5. No association between smoking
and WM volume or WMH burden
(limited evidence).
6. Smoking is associated with
elevated FA in the body of corpus
callosum (limited evidence).
No treatment data available. 1. Smoking is not associated with
reduced resting state rCBF
(limited evidence).
2. Acute administration of nicotine
to smokers is associated with a
bidirectional pattern of rCBF
changes in several regions.
3. Smoking is associated with
reduced brain levels of MAO A
and MAO B.
1. Smoking cessation is associated with
an increase in MAO B levels compa-
rable to those of nonsmokers.
Metabolic
syndrome
1. Higher prevalence of MetS
in persons with SBIs.
2. A greater number of individual
components of MetS is associated
with a greater burden of SBIs.
3. No consensus on the association
of MetS with WMH burden.
4. MetS is associated with lower
FA and higher ADC in the anterior
corpus callosum (limited data).
No treatment data available. 1. MetS is associated with reduced
working memory task–related
activation of multiple brain regions
on fMRI (limited evidence).
1. The use of medications to treat
multiple components of MetS has no
inﬂuence on MetS-associated
reduced brain activation during a
working memory task (limited data).
ADC ¼ apparent diffusion coefﬁcient; BMI ¼ body mass index; BP ¼ blood pressure; CBF ¼ cerebral blood ﬂow; DM ¼ diabetes mellitus; FA ¼ fractional anisotropy; fMRI ¼ functional magnetic resonance
imaging; gCBF ¼ global cerebral blood ﬂow; GM ¼ gray matter; HbA1c ¼ glycosylated hemoglobin; HTN ¼ hypertension; LDL ¼ low-density lipoprotein; MAO ¼ monoamine oxidase; MetS ¼ metabolic
syndrome; rCBF¼ regional cerebral blood ﬂow; rCMRglu¼ regional cerebral glucose metabolic rate; SBIs ¼ silent brain infarcts; SBP¼ systolic blood pressure; VRF¼ vascular risk factor; WM¼white matter;
WMHs ¼ white matter hyperintensities.
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1045signiﬁcantly younger mean age of the untreated hy-
pertensive patient subgroup compared with the
treated group (57.6 vs. 68.2).
Functional brain changes. Cerebral blood ﬂow changes.
There is consensus among reports that a diagnosis
of HTN is associated with abnormally reduced blood
ﬂow during rest throughout the whole brain (global
cerebral blood ﬂow) and in discrete brain areas
(regional cerebral blood ﬂow), and is associated
with bidirectional alterations in cognitive test
performance–related activation of regional brain
blood ﬂow, with some brain regions showing abnor-
mally reduced blood ﬂow and some abnormally
increased blood ﬂow (25–30). The quality of BP control
in hypertensive patients has been positively corre-
lated with brain blood ﬂow in speciﬁc regions
observed during rest in both cross-sectional (29,30)
and longitudinal (25) studies. These data would
suggest a potential for antihypertensive treatment to
reverse the HTN-associated abnormally decreased
brain regional blood ﬂow observed during rest.
Indeed, both global and regional brain blood ﬂow
observed during rest is lower in persons with
untreated HTN compared with normotensive
persons, whereas treatment with antihypertensivemedication nearly normalizes regional brain blood
ﬂow at rest in hypertensive persons (26,29,30), with
a treatment period as short as 6 months to produce
these effects (26,31). However, there is evidence,
although limited, that these antihypertensive
treatment–related improvements in brain blood ﬂow
observed at rest in hypertensive patients may be
transient, wherein such improvements have been
observed at 6, 12, and 24 months after initiation of
antihypertensive treatment, but returned to pre-
treatment abnormally low levels after 36 months of
treatment (31).
The bidirectional nature of regional brain blood
ﬂow changes observed during cognitive task per-
formance in persons with HTN may reﬂect com-
pensatory mechanisms. For example, hypertensive
patients show greater left brain hemispheric blood
ﬂow increases while performing tests of attention
and memory, whereas normotensive patients show
greater right hemispheric brain blood ﬂow increases
while performing the same tests (27). These data
suggest that regional blood ﬂow changes in the brains
of hypertensive patients performing cognitive tests
redistribute to alternate brain regions to maintain
successful performance of these cognitive tests. This
FIGURE 1 How Can Brain Circuit Connectivity Inform Us
About Cardiovascular Health?
A 3-dimensional visualization of normal brain white matter
tracts generated by tractography analysis of data collected by
diffusion tensor imaging (DTI). This analysis uses special tech-
niques of magnetic resonance imaging and computer-based
image analysis to provide insight into the complex white matter
connections between neural networks formed by short con-
nections among different cortical and subcortical brain regions.
DTI can be used to evaluate the integrity of these white matter
connections. Data from this review demonstrate that the same
risk factors for cardiovascular disease also compromise the
integrity of these white matter connections and thus the
normal physiological pattern of synchronized activation/deac-
tivation of these interconnected brain regions (also presented
in this review). These disruptions result in subtle cognitive
impairments. Although not easily recognizable, we hypothesize
that they are sufﬁcient to adversely affect the adoption of
primary prevention measures for cardiovascular events. The use
of sophisticated neuroimaging techniques such as DTI to assess
changes in structure of brain connectivity and related neuro-
imaging techniques to assess functional changes in brain con-
nectivity in persons at risk of cardiovascular disease and events
will enhance our understanding of the role of the brain in the
progression from cardiovascular risk factor to symptomatic
disease.
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tensive patients with better memory performance
show less HTN-related abnormal increases in blood
ﬂow in the prefrontal region and less HTN-related
abnormal muting of blood ﬂow increases in right
hippocampal region (28), 2 important brain blood
ﬂow changes necessary for normal memory perfor-
mance. Also, there appears to be a secondary brain
blood ﬂow compensatory mechanism manifested as
an increase in the correlation of blood ﬂow rates be-
tween brain regions in hypertensive persons per-
forming cognitive tests. Speciﬁcally, hypertensive
patients have shown increased linkage of brain blood
ﬂow increases in the hippocampal and prefrontal re-
gions compared with normotensive persons while
performing memory tests (28). Antihypertensive
treatment appears to facilitate this secondary brain
blood ﬂow compensatory mechanism observed in
hypertensive patients. For example, 1 year of treat-
ment with either lisinopril or atenolol results in
greater linkage of blood ﬂow increases between pre-
frontal, parietal, prefrontal, and hippocampal brain
regions, regions involved in speciﬁc memory pro-
cesses (32). Additionally, diuretic treatment over a
period of 6 months has been shown to improve per-
formance on tests of several different cognitive abil-
ities; these improvements correlate with the
magnitude of blood ﬂow increases in several brain
regions (26) (Online Table 1).
Cerebral glucose metabolic changes. Using positron
emission tomography, patients with HTN at rest have
been shown to have reduced rates of brain glucose
metabolism in regions supplied by the perforator ar-
teries of the circle of Willis (33) and reduced correla-
tions between brain glucose metabolic rates in these
regions (33), suggestive of a reduction in connectivity
between the functioning of neurons in these brain
regions (33).
II. DIABETES MELLITUS. A total of 13 published im-
aging studies of the brain in association with DM are
included in this review (Online Table 2).
Structural brain changes. GM changes. Reports of volu-
metric changes in brain GM of patients with type 2 DM
have been inconsistent across studies, with some re-
ports demonstrating an association between a diag-
nosis of type 2DMandGMvolume loss across thewhole
brain (34,35), whereas others show no GM volume loss
globally in the brain of patients diagnosed with type 2
DM (36–38). However, when assessing speciﬁc brain
regions, a number of reports show the diagnosis of
type 2 DM to be associated with GM volume loss in
discrete brain regions (34,37,39,40), although no
consensus exists on the location of this GM volume
loss (Online Table 2). Additionally, inconsistentassociations between the effectiveness of glycemic
control over time (glycosylated hemoglobin [HbA1c]
levels) and brain GM volume have been observed:
some reports show an inverse relationship between
HbA1c levels and volume of the hippocampus (37),
whereas others show no relationship between HbA1c
levels and volume of speciﬁc GM brain regions (36).
WM changes. Some reports show type 2 DM to be
associated with reduced global brain WM volume
(34), whereas some show regionally speciﬁc WM
volume reductions (34,36). The associations between
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disease have been more inconsistent. Some studies
show signiﬁcant associations between a diagnosis of
type 2 DM and an increased presence of MRI in-
dexes of brain microvascular disease (34–36,39),
whereas others show no such association with type
2 DM (37,38,41). However, even in the studies that
report signiﬁcant associations between type 2 DM
and brain microvascular disease, the type and
location of the MRI indexes of brain microvascular
disease differ between studies (34–36,39) (Online
Table 2). Moreover, limited data suggest the quality
of glycemic control affects the amount of observed
brain microvascular disease, as demonstrated by a
positive correlation between HbA1c level and the
quantity of observed MRI indexes of brain micro-
vascular disease (35).
MRI indexes of the structure (i.e., diffusivity) and
organization (i.e., fractional anisotropy) of brain WM
connecting tracts have also been reported to be
affected by a diagnosis of DM. For example, type 1 DM
has been associated with more disorganized WM
tracts in several brain regions (42,43), with better
long-term glycemic control associated with a greater
degree of preservation of the organization of the brain
WM tracts in some of these regions (42). In addition,
a diagnosis of DM has also been associated with
increased myelin degeneration in a number of the
same brain regions in which increased WM tract
disorganization has been observed (43). Finally,
increased brain WM tract disorganization in several
regions affected by DM has been associated with
poorer cognitive performance (42).
Functional brain changes. Cerebral blood ﬂow changes.
Over all brain regions investigated, regional blood
ﬂow observed at rest is lower in patients with type 2
DM (34), and the normal increase in blood ﬂow
associated with hypercapnea is also lower in patients
with type 2 DM (34).
Cerebral glucose metabolic changes. Similar to the brain
blood ﬂow changes observed in patients with HTN,
both type 2 DM and pre-diabetes are associated with a
bidirectional alteration and a redistributed pattern of
brain glucose metabolism in patients performing tests
of memory function (2 proposed compensatory
mechanisms for the brain metabolism dysfunction
that accompanies DM). Speciﬁcally, patients with
type 2 DM and pre-diabetes show a more widespread
pattern of brain glucose metabolism, extending to
brain regions adjacent to those activated in
nondiabetic patients while performing tests of
memory function (44) (Online Table 2). Moreover,
better performance of pre-diabetic and diabetic
patients on memory tests has been associated with agreater ability to increase brain glucose metabolism
during performance of these memory tests in regions
normally activated (44). Furthermore, a greater
decrease in the ability of body’s cells to respond to
the actions of the insulin has been associated with
reduced brain glucose metabolism during rest in a
number of brain regions (44) (Online Table 2).
Brain regional activation (fMRI) changes. Patients with
type 2 DM have demonstrated reduced synchronized
activity between several speciﬁc brain regions,
observed by functional magnetic resonance imaging
(fMRI) (reduced functional connectivity), regions
normally engaged when patients are left to think to
themselves undisturbed (referred to as the default
mode network) (40,45) (Online Table 2). Moreover,
the reduction in functional connectivity of this free-
thinking brain network is accompanied by impaired
cognitive performance (45). When parsing patients
with type 1 DM on the basis of the presence or absence
of microangiopathy (a group of microvascular abnor-
malities including vessel wall remodeling, media hy-
pertrophy, and increased vascular wall stiffness), a
mixed pattern of functional connectivity changes
compared with nondiabetic patients emerges. Pa-
tients with type 1 DM and microangiopathy have
demonstrated decreased functional connectivity
compared with nondiabetic patients in 5 different
brain networks: 1) the network of brain regions that
subserves motor and sensory tasks (sensorimotor
network); 2) the network of brain regions that sub-
serves visual processing (secondary visual network);
3) the network of brain regions that subserves atten-
tion (ventral attention network); 4) the network of
brain regions that subserves the processing of audi-
tory and language information (language-processing
network); and 5) the network of brain regions that
subserves working memory (a form of short-term
memory in which information is stored and manipu-
lated) (left frontoparietal network) (46). In contrast,
type 1 DM patients without microangiopathy have
demonstrated increased connectivity in 2 of these
brain networks compared with nondiabetic patients:
the sensorimotor and secondary visual networks
compared with nondiabetic patients: the network of
brain regions that subserves motor and sensory
tasks and the network of brain regions that subserves
visual processing. Type 1 DM patients without
microangiopathy have demonstrated decreased con-
nectivity in the other 3 brain networks compared with
nondiabetic patients: 1) the network of brain regions
that subserves attention; 2) the network of brain
regions that subserves the processing of auditory
and language information; and 3) the network of
brain regions that subserves working memory (46)
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networks of diabetic patients without micro-
angiopathy (which we may consider an earlier stage in
the course of diabetes compared with diabetic patients
with microangiopathy) has also been observed early in
the process of other pathological brain states such as
multiple sclerosis and mild cognitive impairment
(47,48). One explanation for this early-stage increased
connectivity is that it is a compensatory reaction
characterized by functional reorganization in attempts
to maintain cognitive functions, occurring in response
to early subtle brain damage. Indeed, as the severity of
multiple sclerosis increases, brain network connec-
tivity decreases (48).
III. ADIPOSITY. A total of 15 published imaging
studies of the brain in association with measures of
adiposity are included in this review (Online Table 3).
Structural brain changes. Global changes. Various in-
dexes of increased adiposity such as increased body
mass index (BMI), increased waist circumference,
increased subcutaneous adipose tissue, and increased
visceral adipose tissue have all been associated with
total brain volume decreases (49–51).
Gray matter changes. Indexes of increased adiposity
(most frequently BMI), have been consistently asso-
ciated with regional brain GM volume decreases,
although the location of these volume decreases has
been inconsistent (52–55) (Online Table 3). Interest-
ingly, some investigations report signiﬁcant brain GM
volume reductions in those considered obese (BMI
S30) (51), whereas others report signiﬁcant brain GM
volume reductions in those considered simply over-
weight (BMI >25) (52,55). Indeed, the magnitude of
cognitive impairment is associated with the magni-
tude of brain GM volume loss volume in those regions
signiﬁcantly affected by increased adiposity (53).
Finally, a higher BMI has been associated with
decreased MRI neurochemical markers of neuronal
integrity (N-acetylaspartate) in several brain GM re-
gions (56,57) (Online Table 3).
WM changes. Reported brain WM volumetric changes
associated with indexes of adiposity have been more
inconsistent. Some have reported increased adiposity
to be associated with brain WM volume increases (53),
some have reported brain WM volume reductions
(52), and yet others have reported no brain WM
volumetric changes (51). We identiﬁed only 1 study
for inclusion that evaluated the extent of MRI
markers of brain microvascular disease in association
with measures of adiposity that reported no associa-
tion between several different indexes of adiposity
and brain microvascular disease (50) (Online Table 3).
Brain WM neurochemical changes indicate greater
adiposity to be associated with MRI indexes ofdecreased neuronal integrity in several brain WM
regions (56). Moreover, MRI indexes of brain WM
microstructural changes indicate that greater
adiposity is associated with reduced brain WM con-
necting tract coherence in several regions, most
consistently in the corpus callosum (largest WM
structure in the brain, connecting the left and right
cerebral hemispheres) (58–61), increased axonal
damage in brain WM (59), and increased myelin
damage in brain WM (61) (Online Table 3). Interest-
ingly, greater aerobic ﬁtness has been associated with
greater coherence of brain WM in the same persons
demonstrating a deleterious effect of increased
adiposity on brain WM coherence (58).
Functional brain changes. Cerebral blood ﬂow changes.
Only a single study was identiﬁed for inclusion eval-
uating the effects of adiposity of brain blood ﬂow that
demonstrated a global decrease in brain blood ﬂow in
persons with increased adiposity (62).
Cerebral glucose metabolic changes. Negative correla-
tions between adiposity and glucose metabolic rate
in anterior regions of the brain have been identi-
ﬁed (63), with a lower glucose metabolic rate in
these regions associated with poorer cognitive
performance (63).
IV. HYPERLIPIDEMIA. A total of 8 published imaging
studies of the brain in association with hyperlipid-
emia are included in this review (Online Table 4).
Structural brain changes. GM changes. Higher total
cholesterol and low-density lipoprotein (LDL) levels
have been associated with lower total brain GM
volume (64). Moreover, lower levels of high-density
lipoprotein (HDL) cholesterol and higher levels of
total cholesterol and non-HDL cholesterol have been
associated with MRI indexes of reduced neuronal
integrity in posterior brain regions (65).
WM changes. Structural MRI has not revealed any
signiﬁcant associations between lipid levels and WM
volume (64) nor with MRI indexes of brain micro-
vascular disease (66–68). MRI indexes of brain WM
tract organization have been more revealing. For
example, higher LDL, total cholesterol, and HDL have
all been associated with widespread decreases in the
coherence of brain WM tracts lateralized to the right
hemisphere (69), with LDL levels showing the stron-
gest associations and additional associations with
imaging indexes of myelin integrity (69). Although
higher triglyceride levels have been associated with
decreased brain WM tract coherence, this association
is weaker and less widespread compared with other
lipid measures (69). Finally, treatment with lipid-
lowering medication seems to have no effect on
reversing the changes in brain WM associated with
increased lipid measures (69).
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Patients with hypertriglyceridemia have demon-
strated decreased blood ﬂow in select regions of the
brain (65) (Online Table 4).
Cerebral glucose metabolic changes. Higher total
cholesterol has been associated with decreased
glucose metabolism in several brain regions (70)
(Online Table 4). Use of lipid-lowering drugs had no
effect on these ﬁndings (70). Moreover, a higher ge-
netic risk of abnormal cholesterol has been associated
with lower glucose metabolism in the same brain re-
gions affected by high total cholesterol (71).
V. SMOKING. A total of 12 published imaging studies
of the brain in association with smoking are included
in this review (Online Table 5).
Structural brain changes. Global changes. Smokers have
demonstrated signiﬁcantly smaller total brain volume
compared with nonsmokers (72). Moreover, greater
lifetime exposure to tobacco has been associated with
smaller total brain volume (72).
GM changes. Smokers have shown signiﬁcantly
smaller GM volume and lower GM density in multiple
brain regions compared with never smokers (73,74)
(Online Table 5). Among those who smoke, a greater
lifetime exposure tobacco has been associated with
smaller GM volume in several brain regions (73,74).
Smoking has also been associated with MRI indexes
of reduced neuronal integrity in the hippocampus
(75), and increased cellular turnover in anterior
cingulate cortex (75).
White matter changes. Structural MRI has revealed no
signiﬁcant effects of smoking on WM volume (76), nor
MRI indexes of brain microvascular disease (77).
However, smoking has been associated with
increased coherence of brain WM tracts in the body of
the corpus callosum (76).
Functional brain changes. Cerebral blood ﬂow changes.
Global brain blood ﬂow during rest has not been show
to differ between smokers and nonsmokers (77).
However, among smokers, acute administration of
nicotine has been reported to induce a reduction in
global brain blood ﬂow during rest, more in the right
than left hemisphere (78). Moreover, when consid-
ering individual brain regions, a bidirectional pattern
of brain regional blood ﬂow changes during rest has
been seen in smokers acutely administered tobacco
products, with some regions showing reductions and
some increases (79) (Online Table 5).
Neurochemical and receptor changes. Monoamine oxi-
dase B levels have been shown to be reduced in the
brains of smokers compared with nonsmokers
(80,81). In addition, nicotinic acetylcholine receptor
density has been shown to be greater in several brain
regions in smokers compared with nonsmokers (82)(Online Table 5). Smokers acutely exposed to ciga-
rettes show greater post-smoking imaging indexes of
increased dopamine release in several brain regions
compared with smokers with no acute exposure (83).
VI. METABOLIC SYNDROME. A total of 7 published
imaging studies of the brain in association with MetS
are included in this review (Online Table 6).
Structural brain changes. GM changes. None of the
selected studies for inclusion in this review assessed
for brain GM changes in association with MetS.
WM changes. The prevalence of MetS has been re-
ported to be higher in patients with silent brain in-
farcts (SBIs), an MRI-based indication of subclinical
cerebrovascular disease (84,85). Moreover, among
those persons with SBIs, those with a greater number
of individual components of MetS demonstrated a
greater burden of SBIs (84,85). The data on MRI
indexes of brain microvascular disease are more
mixed, with some showing no increase in MRI indexes
of brain microvascular disease in persons with MetS
(86,87), whereas others found increased MRI indexes
of brain microvascular disease in persons with MetS
(88). Limited data have demonstrated decreased
organization and cellularity of the anterior portion of
the largest WM connecting structure in the brain
(corpus callosum) of patients with MetS (89). Among
those with a diagnosis of MetS, MRI indexes of the
organization of this WM connecting structure
correlate with performance on various cognitive tasks
(86) (Online Table 6).
Functional brain changes. Brain regional activation
(fMRI) changes. MetS has been associated with
reduced activation of several brain regions in pa-
tients performing cognitive tasks, detected by fMRI
(90). Moreover, lower activation of these brain re-
gions was associated with poorer performance on
these cognitive tasks (90) (Online Table 6). Finally,
these ﬁndings remained signiﬁcant after controlling
for the use of all medications used to treat compo-
nents of MetS (90).
DISCUSSION
The results of this systematic review demonstrate
that patients without symptomatic cardiovascular,
cerebrovascular, or peripheral vascular disease but
harboring risk factors for these diseases show signif-
icant structural and functional brain imaging changes
(Table 1). Speciﬁcally, the risk factors of HTN, DM,
increased adiposity, hyperlipidemia, and smoking are
all independently associated with brain imaging
changes. Moreover, the presence of an increasing
number of individual VRF appears to increase the
magnitude of these brain imaging changes as implied
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important clinical manifestation of these VRF-related
structural and functional brain imaging changes in
these otherwise healthy persons is cognitive
impairment.
The greater consistency of VRF-related functional
brain imaging changes compared with structural
changes in these asymptomatic at-risk persons, spe-
ciﬁcally, reductions in brain blood ﬂow and glucose
metabolism during rest, suggest early pathological
changes in brain microcirculation affecting cerebral
hemodynamics before the occurrence of detectable
structural changes caused by atherosclerosis. Some
potential changes include damage to mechanisms
regulating vasomotor tone leading to enhanced
vasoconstriction or reduced vasodilator responses
(91), hypertrophy of the smooth muscles of pre-
capillary resistance vessels, or perhaps reductions in
the density of arterioles or capillaries in speciﬁc
vascular beds (92,93).
Moreover, the redistribution of the normal pattern
of hemodynamic and metabolic brain activation dur-
ing a cognitive challenge observed in these asymp-
tomatic patients harboring VRFs may indicate a
compensatory mechanism invoked in response to
early-stage dysfunction of the neuroarchitectural
network that typically would support these cognitive
tasks. These points are best illustrated in the obser-
vations of van Duinkerken et al. (46) wherein patients
with DM with cerebral microangiopathy show
decreased connectivity in 5 functional brain net-
works, whereas patients with DM without cerebral
microangiopathy show decreased connectivity in 3 of
these functional networks and increased connectivity
in the remaining 2. This supports the notion of
functional reorganization occurring in response to
early subtle brain damage (effect of diabetes without
microangiopathy), followed by a failing of this func-
tional reorganization as disease severity increases
(diabetes with microangiopathy). To investigate the
possible structural substrates of the observed redis-
tribution of the normal pattern of hemodynamic and
metabolic brain activation during a cognitive chal-
lenge in asymptomatic persons harboring VRFs,
correlations between metrics of WM tract connec-
tivity demonstrated by MRI within and between co-
ordinated brain regions would be revealing. Such
techniques for visualizing brain complex white mat-
ter connections between neural networks formed by
short connections among different cortical and
subcortical brain regions currently exist and can be
generated by tractography analysis of data collected
by diffusion tensor imaging as depicted in Figure 1.
Unfortunately, nearly all of the studies included inthis review failed to acquire such data in conjunction
with hemodynamic and metabolic brain data. Clearly,
such investigations are warranted in the future.
Given that a greater number of patients in our ag-
ing population are projected to experience the
development of mild forms of vascular cognitive
impairment, this trend necessitates a better under-
standing of the mechanisms underlying their devel-
opment and potential interventions to reverse or halt
their progression. Indeed, cognition is the most
important determinant of health status, quality of
life, and functional ability in older age (94). Dimin-
ished cognitive capacity adversely affects a person’s
ability to beneﬁt from treatment for other medical
problems (95). Given that the VRFs associated with
the brain changes and cognitive impairments
reviewed here are potentially modiﬁable, manage-
ment of these modiﬁable factors could be a primary
line of treatment. Indeed, the relationships between
indexes of how effectively these VRFs are controlled
(i.e., BP, HbA1c, BMI, total cholesterol, and LDL) and
the severity of imaging abnormalities and related
cognitive impairments reviewed here suggest that
adequate treatment of these risk factors may have
beneﬁcial effects on brain function. Unfortunately,
among the publications included in this review, ana-
lyses of medication effects on VRF-related brain im-
aging changes were scarce, but the limited evidence is
compelling nonetheless. For example, antihyperten-
sive treatment consistently blunted and/or reversed
the decrease in global and regional brain blood ﬂow
and associated cognitive dysfunction in hypertensive
patients. Therefore, future investigations of the
treatment effects of VRFs on brain function and
related cognitive abilities are sorely needed.
A precise summary of the somewhat disparate
ﬁndings of brain imaging studies of VRFs was chal-
lenging due to a number of factors inﬂuencing out-
comes. Although the selection of studies for inclusion
in this review was based, in part, on the conduct of a
minimal number of statistical corrections for con-
founds such as age, sex, and the presence of other
VRFs, these variables did differ between studies.
Other disparate factors that could have inﬂuenced the
outcome of this review include age at onset of dis-
ease, duration of disease, and treatment status of the
groups for these particular VRFs. Such confounds
were inconsistently accounted for or data not pro-
vided at all. Moreover, studies differed in how the
particular risk factor was deﬁned (i.e., some studies
used a dichotomous designation for HTN, whereas
others used SBP and DBP as continuous variables in
their analyses). Additionally, structural imaging
methodology varied signiﬁcantly between studies
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brain region of interest or the methodology of brain
tissue type segmentation (i.e., GM, WM, cerebrospi-
nal ﬂuid), grading of WMH burden, or even the type
of subclinical cerebrovascular pathology assessed.
Moreover, comparing the ﬁndings of functional brain
imaging studies that used varying techniques for
quantifying hemodynamic and metabolic changes
was challenging.
Despite these limitations, this review represents
an important endeavor given that the earlyidentiﬁcation and initiation of adequate treatment of
these modiﬁable risk factors before the development
of irreversible end-organ damage in the brain is an
important clinical challenge that we must continue to
address.
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